Pharmafile Logo
Pharmafocus logo
Advanced Search

Aubagio

Showing 10 posts of 10 posts found.

Novartis announce robust Phase 3 trials for ofatumumab in MS

September 16, 2019
Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis

Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …

News
Biogen Idec logo

NICE final ‘yes’ for Biogen’s MS pill

August 27, 2014
Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya

In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …

News
Sanofi’s chief executive Christopher Viehbacher image

Analysts ‘disappointed’ by Sanofi guidance

February 6, 2014
Sales and Marketing Aubagio, Plavix, Sanofi, q4, sales

Sanofi has announced a mixed bag for its full year results as analysts have questioned why its forecasts for the …

News
Biogen Idec image

Biogen Idec’s MS drug gets European approval

February 4, 2014
Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera

Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …

News
Aubagio image

NICE recommends Aubagio

January 22, 2014
Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya

NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …

News
sanofi_building

Sanofi hit hard by Lemtrada rejection

January 2, 2014
Medical Communications, Research and Development, Sales and Marketing Aubagio, FDA, Genzyme, Lemtrada, MS, Sanofi

News
nice_sign

NICE: we need more Aubagio data

September 18, 2013
Sales and Marketing Aubagio, Genzyme, MS, NICE, Sanofi

News
sanofi_chris_viehbacher

Sanofi’s Lemtrada given European go ahead

September 18, 2013
Research and Development, Sales and Marketing Aubagio, Lemtrada, MS, Sanofi, gilenya

News
Aubagio image

Aubagio approved in Europe

September 3, 2013
Sales and Marketing Aubagio, Genzyme, Rebif, Sanofi, tecfidera

Sanofi’s once-daily multiple sclerosis pill Aubagio has been authorised by European regulators, paving the way for it to continue its …

News
Genzyme

Genzyme MS drug approved in US

September 13, 2012
Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis

US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …

News
The Gateway to Local Adoption Series

Latest content

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026